CPA
AVIR icon

Capital Performance Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Capital Performance Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31
Closed -$104 – 402
2024
Q3 		$104 Buy
+31
New +$112 ﹤0.01% 2690

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Performance Advisors's AVIR Position: Q4 2024 in Review

Capital Performance Advisors sold out of Atea Pharmaceuticals (AVIR) in Q4 2024, closing a stake of 31 shares — an estimated $104 sold.

Capital Performance Advisors first reported a position in AVIR in Q3 2024 and held it in 1 quarter. The position peaked at $104 in Q3 2024. 106 funds tracked by Wall St. Rank hold AVIR as of Q4 2024.

  • Capital Performance Advisors reported no remaining Atea Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 31 Atea Pharmaceuticals shares in Q4 2024, an estimated $104.
  • Capital Performance Advisors first reported a position in Atea Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Atea Pharmaceuticals position peaked at $104 in Q3 2024.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.